137 related articles for article (PubMed ID: 36070058)
21. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
22. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Martin M; Zielinski C; Ruiz-Borrego M; Carrasco E; Turner N; Ciruelos EM; Muñoz M; Bermejo B; Margeli M; Anton A; Kahan Z; Csöszi T; Casas MI; Murillo L; Morales S; Alba E; Gal-Yam E; Guerrero-Zotano A; Calvo L; de la Haba-Rodriguez J; Ramos M; Alvarez I; Garcia-Palomo A; Huang Bartlett C; Koehler M; Caballero R; Corsaro M; Huang X; Garcia-Sáenz JA; Chacón JI; Swift C; Thallinger C; Gil-Gil M
Ann Oncol; 2021 Apr; 32(4):488-499. PubMed ID: 33385521
[TBL] [Abstract][Full Text] [Related]
23. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
24. Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
Battisti NML; Kingston B; King J; Denton A; Waters S; Sita-Lumsden A; Rehman F; Stavraka C; Kristeleit H; Sawyer E; Houghton D; Davidson N; Howell S; Choy J; Harper P; Roylance R; Fharat R; Mohammed K; Ring A; Johnston S
Breast Cancer Res Treat; 2019 Apr; 174(3):731-740. PubMed ID: 30656459
[TBL] [Abstract][Full Text] [Related]
25. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
[TBL] [Abstract][Full Text] [Related]
26. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
Lee J; Im SA; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park YH
Cancer Res Treat; 2021 Jul; 53(3):695-702. PubMed ID: 33332933
[TBL] [Abstract][Full Text] [Related]
27. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
[TBL] [Abstract][Full Text] [Related]
28. Palbociclib combined with endocrine therapy in heavily pretreated HR
Manso L; Hernando C; Galán M; Oliveira M; Cabrera MA; Bratos R; Rodríguez CA; Ruiz-Borrego M; Blanch S; Llombart-Cussac A; Delgado-Mingorance JI; Álvarez-Busto I; Gallegos I; González-Cortijo L; Morales S; Aguirre E; Hernando BA; Ballesteros A; Alés-Martínez JE; Reboredo C; Oltra A; González-Cao M; Santisteban M; Malón D; Echeverría I; García-Garre E; Vega E; Servitja S; Andrés R; Robles CE; López R; Galve E; Echarri MJ; Legeren M; Moreno F
Breast; 2020 Dec; 54():286-292. PubMed ID: 33242755
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer.
Wang W; Lei W; Fang Z; Jiang R; Wang X
BMC Cancer; 2024 Jan; 24(1):1. PubMed ID: 38166784
[TBL] [Abstract][Full Text] [Related]
30. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
Malorni L; Curigliano G; Minisini AM; Cinieri S; Tondini CA; D'Hollander K; Arpino G; Bernardo A; Martignetti A; Criscitiello C; Puglisi F; Pestrin M; Sanna G; Moretti E; Risi E; Biagioni C; McCartney A; Boni L; Buyse M; Migliaccio I; Biganzoli L; Di Leo A
Ann Oncol; 2018 Aug; 29(8):1748-1754. PubMed ID: 29893790
[TBL] [Abstract][Full Text] [Related]
31. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Llombart-Cussac A; Pérez-García JM; Bellet M; Dalenc F; Gil-Gil M; Ruíz-Borrego M; Gavilá J; Sampayo-Cordero M; Aguirre E; Schmid P; Marmé F; Di Cosimo S; Gligorov J; Schneeweiss A; Albanell J; Zamora P; Wheatley D; Martínez-de Dueñas E; Amillano K; Malfettone A; Cortés J;
JAMA Oncol; 2021 Dec; 7(12):1791-1799. PubMed ID: 34617955
[TBL] [Abstract][Full Text] [Related]
32. Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ
N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613
[TBL] [Abstract][Full Text] [Related]
33. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
Harbeck N; Iyer S; Turner N; Cristofanilli M; Ro J; André F; Loi S; Verma S; Iwata H; Bhattacharyya H; Puyana Theall K; Bartlett CH; Loibl S
Ann Oncol; 2016 Jun; 27(6):1047-1054. PubMed ID: 27029704
[TBL] [Abstract][Full Text] [Related]
34. [Clinical observation of palbociclib combined with endocrine therapy in hormone receptor positive and HER2 negative advanced breast cancer].
Lyu HM; Niu LM; Zhang MW; Zeng HA; Zhao SN; Liu ZZ; Yan M
Zhonghua Yi Xue Za Zhi; 2021 Nov; 101(44):3625-3630. PubMed ID: 34823278
[No Abstract] [Full Text] [Related]
35. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Turner NC; Slamon DJ; Ro J; Bondarenko I; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; André F; Puyana Theall K; Huang X; Giorgetti C; Huang Bartlett C; Cristofanilli M
N Engl J Med; 2018 Nov; 379(20):1926-1936. PubMed ID: 30345905
[TBL] [Abstract][Full Text] [Related]
36. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S
Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671
[TBL] [Abstract][Full Text] [Related]
37. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
Pizzuti L; Giordano A; Michelotti A; Mazzotta M; Natoli C; Gamucci T; De Angelis C; Landucci E; Diodati L; Iezzi L; Mentuccia L; Fabbri A; Barba M; Sanguineti G; Marchetti P; Tomao S; Mariani L; Paris I; Lorusso V; Vallarelli S; Cassano A; Aroldi F; Orlandi A; Moscetti L; Sergi D; Sarobba MG; Tonini G; Santini D; Sini V; Veltri E; Vaccaro A; Ferrari L; De Tursi M; Tinari N; Grassadonia A; Greco F; Botticelli A; La Verde N; Zamagni C; Rubino D; Cortesi E; Magri V; Pomati G; Scagnoli S; Capomolla E; Kayal R; Scinto AF; Corsi D; Cazzaniga M; Laudadio L; Forciniti S; Mancini M; Carbognin L; Seminara P; Barni S; Samaritani R; Roselli M; Portarena I; Russo A; Ficorella C; Cannita K; Carpano S; Pistelli M; Berardi R; De Maria R; Sperduti I; Ciliberto G; Vici P
J Cell Physiol; 2019 Jun; 234(6):7708-7717. PubMed ID: 30536609
[TBL] [Abstract][Full Text] [Related]
38. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
[TBL] [Abstract][Full Text] [Related]
39. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
[TBL] [Abstract][Full Text] [Related]
40. Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
Lynce F; Blackburn MJ; Zhuo R; Gallagher C; Hahn OM; Abu-Khalaf M; Mohebtash M; Wu T; Pohlmann PR; Dilawari A; Tiwari SR; Chitalia A; Warren R; Tan M; Shajahan-Haq AN; Isaacs C
Cancer; 2021 Oct; 127(19):3622-3630. PubMed ID: 34157782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
